Cell Therapy · uk
Putting the Brakes on the Immune Response: First Patients with Autoimmune Diseases Receive Engineered Regulatory T Cells
The first three patients in the CHILL trial have received QEL-005, and the study has advanced to the second dose cohort following a safety review. The therapy aims to calm uncontrolled immune responses using patients’ own regulatory T cells, but whether it can improve disease—and how long any benefit might last—remains to be answered by human data.
For patients with autoimmune diseases who respond poorly to existing treatments, getting the immune system to stop damaging the body’s own tissues remains a treatment challenge. An early human trial in the UK is exploring a new approach: engineering patients’ own regulatory T cells, which help restrain immune responses, and infusing them back into the body. Oxford University Hospitals and Leeds Teaching Hospitals announced on October 21 that the study, called CHILL, had completed dosing of its first patients and advanced to the second planned dose cohort following a safety review.
According to the progress reported by the two hospitals, the first participant worldwide received treatment in Leeds, followed by two participants in Oxford, making up the three-person first dose cohort. Sponsored by Quell Therapeutics, the trial is evaluating its investigational cell therapy QEL-005 for refractory rheumatoid arthritis and diffuse cutaneous systemic sclerosis. This milestone allows the study to continue, but does not yet establish that the treatment is effective.
QEL-005 uses regulatory T cells, also known as Tregs. These cells naturally help maintain immune balance and suppress excessive responses. The research team engineers patients’ cells in the laboratory to carry a chimeric antigen receptor (CAR) that recognizes CD19, a marker on B cells. The aim is for these regulatory cells to act when they come into proximity with B cells, dampening the immune activity that drives disease. Whether this regulation can produce lasting improvement in humans is precisely what the trial seeks to test.
The UK Health Research Authority’s study summary describes CHILL as a first-in-human, Phase I/II, single-arm, open-label, multicenter trial. Participants first undergo leukapheresis to collect cells. Manufacturing QEL-005 takes approximately six to eight weeks, after which it is administered as a single intravenous infusion, with an overnight hospital stay for monitoring. In addition to assessing the safety of different doses, the study will explore whether disease symptoms and quality of life improve.
Safety is the first hurdle cleared so far. Quell announced on the same day that the first three participants experienced no dose-limiting toxicities, treatment-related adverse events of special interest, or serious adverse events, and all met discharge criteria on the morning after infusion. However, these data come from early observations in a very small number of patients and cannot rule out less common or later-onset risks. Clearance to enter the next dose cohort also does not mean that the therapy’s overall safety has been established.
Assessing efficacy will also take time. CHILL has no concurrent control group, and both patients and researchers know which treatment is being given. Even if symptoms subsequently improve, the influence of factors such as natural fluctuations in disease will need careful assessment. The company expects to release initial clinical data in the first half of 2027, when there will be more evidence to examine whether these cells produce changes in disease activity.
Whether a single infusion can deliver long-term control is one of the study’s most anticipated—and still unanswered—questions. Under the study plan, safety follow-up will extend to 15 years after dosing. There remains a gap that clinical evidence must fill between the first patients successfully completing treatment and confirmation that the cells can continue to function consistently in the body.